Edition:
United States

Momenta Pharmaceuticals Inc (MNTA.O)

MNTA.O on Nasdaq

14.75USD
26 May 2017
Change (% chg)

$-0.25 (-1.67%)
Prev Close
$15.00
Open
$14.95
Day's High
$15.05
Day's Low
$14.68
Volume
584,109
Avg. Vol
816,624
52-wk High
$19.90
52-wk Low
$9.66

Select another date:

Tue, May 2 2017

BRIEF-Momenta Pharmaceuticals Q1 loss per share $0.46

* Momenta pharmaceuticals reports first quarter 2017 financial results

BRIEF-Momenta Pharmaceuticals says effective May 1, 2017, Matthew Ottmer will no longer serve as COO of Co

* Momenta pharmaceuticals inc says effective may 1, 2017, matthew ottmer will no longer serve as chief operating officer of co Source text (http://bit.ly/2qpub66) Further company coverage:

BRIEF-Momenta Pharmaceuticals says U.S. Court of Appeals reversed district court's dismissal filed by Amphastar Pharma against Co

* Momenta Pharmaceuticals- on March 6, U.S. Court of Appeals for first circuit reversed district court's dismissal filed by Amphastar Pharma against Co

UPDATE 1-FDA warns Pfizer over contaminated drugs at Kansas plant

Feb 28 The U.S. Food and Drug Administration said Pfizer Inc's process for manufacturing sterile injectable drugs at a plant in McPherson, Kansas, was "out of control" and put patients at risk, according to a warning letter made public on Tuesday.

BRIEF-Momenta Pharmaceuticals Q4 earnings per share $0.60

* Momenta Pharmaceuticals reports fourth quarter and year end 2016 financial results

BRIEF-Momenta Pharmaceuticals announces FDA warning letter to contracted Glatopa

* Momenta Pharmaceuticals announces FDA warning letter to contracted glatopa (glatiramer acetate injection) fill/finish manufacturer

BRIEF-Momenta Pharmaceuticals announces HSR clearance

* Momenta Pharmaceuticals announces Hart-Scott-Rodino clearance for collaboration and license agreement with CSL

BRIEF-Momenta Pharmaceuticals announces district court decision to invalidate Teva Pharmaceuticals patents in copaxone 40 mg/ml litigation

* Momenta Pharmaceuticals announces district court decision to invalidate Teva Pharmaceuticals patents in copaxone 40 mg/ml litigation Source text for Eikon: Further company coverage:

BRIEF-Momenta provides year-end 2016 corporate update

* Momenta Pharmaceuticals Inc - reiterated its non-gaap operating expense guidance of approximately $40 - $45 million for Q4 of 2016

Select another date:

More From Around the Web